Target Name: FEM1A
NCBI ID: G55527
Other Name(s): FEM1a | fem-1 homolog A | EPRAP | FEM1A_HUMAN | Protein fem-1 homolog A | Prostaglandin E receptor 4-associated protein | Fem-1 homolog A | FEM1-alpha | prostaglandin E receptor 4-associated protein

Understanding FEM1a: Potential Drug Target and Biomarker for Cancer

Fem1a, a protein encoded by the FEM1 gene, is a key regulator of cell growth, differentiation, and survival in females. It plays a vital role in the development and maintenance of tissues such as the uterus, fallopian tubes, and ovarian cancer. Despite its importance, little is known about the molecular mechanisms underlying its function.

The FEM1 gene has been implicated in various diseases, including infertility, endometriosis, and ovarian cancer. It has also been implicated in the development of cancer stem cells. Therefore, it is of great interest to study the function of FEM1a as a drug target or biomarker.

Drug Target

FEM1a has been identified as a potential drug target due to its involvement in various cellular processes that are crucial for cancer development. Several studies have shown that inhibition of FEM1a can lead to the inhibition of cancer cell growth and the regression of cancer stem cells.

One of the potential drug targets for FEM1a is the inhibition of the transcription factor, NF-kappa-B. NF-kappa-B is a non-coding RNA molecule that plays a vital role in regulating gene expression and cell signaling. It is activated in response to various stimuli, including cancer-promoting signals.

FEM1a has been shown to regulate the activity of NF-kappa-B, which suggests that it may be a good target for cancer treatment. Several studies have shown that inhibition of FEM1a can lead to the inhibition of NF-kappa-B activity and the regression of cancer stem cells.

Another potential drug target for FEM1a is the inhibition of the protein, PDGF-BB. PDGF-BB is a cell-signaling protein that plays a vital role in the development and maintenance of tissues. It is involved in the regulation of cell growth, differentiation, and survival.

FEM1a has been shown to regulate the activity of PDGF-BB, which suggests that it may be a good target for cancer treatment. Several studies have shown that inhibition of FEM1a can lead to the inhibition of PDGF-BB activity and the regression of cancer stem cells.

Biomarker

FEM1a can also serve as a biomarker for cancer diagnosis and monitoring. The expression of FEM1a has been shown to be associated with the development and progression of various cancers, including breast, ovarian, and prostate cancers.

FEM1a has also been shown to be involved in the regulation of cellular processes that are crucial for cancer stem cell maintenance. Therefore, it may be a useful biomarker for the diagnosis and monitoring of cancer stem cells.

Conclusion

In conclusion, FEM1a is a protein that plays a vital role in the development and maintenance of tissues in females. Its function is not well understood, but it has been implicated in various diseases, including infertility, endometriosis, and ovarian cancer. In addition, FEM1a has been shown to be a potential drug target and biomarker for cancer treatment. Further studies are needed to fully understand its role in cancer development and treatment.

Protein Name: Fem-1 Homolog A

Functions: Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation (PubMed:29779948, PubMed:33398168, PubMed:33398170). The C-degron recognized by the DesCEND pathway is usually a motif of less than ten residues and can be present in full-length proteins, truncated proteins or proteolytically cleaved forms (PubMed:29779948, PubMed:33398168, PubMed:33398170). The CRL2(FEM1A) complex specifically recognizes proteins with an arginine at the C-terminus: recognizes and binds proteins ending with -Lys/Arg-Xaa-Arg and -Lys/Arg-Xaa-Xaa-Arg C-degrons, such as SIL1 or OR51B2, leading to their ubiquitination and degradation (PubMed:33398168, PubMed:33398170). Promotes ubiquitination and degradation of SLBP (PubMed:28118078). Involved in PGE2-EP4-mediated inhibition of inflammation of macrophages via interaction with NFKB1 and PTGER4 (By similarity). Promotes inflammation in brain microglia through MAP2K4/MKK4-mediated signaling (By similarity)

More Common Targets

FEM1AP4 | FEM1B | FEM1C | FEN1 | FENDRR | FER | FER1L4 | FER1L5 | FER1L6 | FER1L6-AS1 | FER1L6-AS2 | FERD3L | FERMT1 | FERMT2 | FERMT3 | Ferritin | FES | Fetal Hemoglobin (HbF) | FETUB | FEV | FEZ1 | FEZ2 | FEZF1 | FEZF1-AS1 | FEZF2 | FFAR1 | FFAR2 | FFAR3 | FFAR4 | FGA | FGB | FGD1 | FGD2 | FGD3 | FGD4 | FGD5 | FGD5-AS1 | FGD5P1 | FGD6 | FGF1 | FGF10 | FGF10-AS1 | FGF11 | FGF12 | FGF12-AS2 | FGF13 | FGF13-AS1 | FGF14 | FGF14-AS1 | FGF14-AS2 | FGF14-IT1 | FGF16 | FGF17 | FGF18 | FGF19 | FGF2 | FGF20 | FGF21 | FGF22 | FGF23 | FGF3 | FGF4 | FGF5 | FGF6 | FGF7 | FGF7P3 | FGF7P5 | FGF7P6 | FGF8 | FGF9 | FGFBP1 | FGFBP2 | FGFBP3 | FGFR1 | FGFR1OP2 | FGFR2 | FGFR3 | FGFR3P1 | FGFR4 | FGFRL1 | FGG | FGGY | FGL1 | FGL2 | FGR | FH | FHAD1 | FHDC1 | FHF Complex | FHIP1A | FHIP1B | FHIP2A | FHIP2B | FHIT | FHL1 | FHL2 | FHL3 | FHL5 | FHOD1 | FHOD3